Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.35 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937044 | 1.00 | NPFFR1 (0.35) | NPFFR1NPFFR2ALDH1A1LMNAHTT | |
| SCHEMBL26695089 | 0.82 | ALDH1A1 (0.33) | ALDH1A1LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL29344227 | 0.80 | ALDH1A1 (0.33) | ALDH1A1LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL29344229 | 0.70 | MEN1 (0.35) | — | |
| SCHEMBL22583779 | 0.69 | RXFP1 (0.36) | LMNAMAPTTSHR | |
| SCHEMBL30606049 | 0.68 | ALDH1A1 (0.35) | NPFFR1NPFFR2ALDH1A1LMNAHTT | |
| SCHEMBL30708738 | 0.65 | MAPT (0.36) | ALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL23609346 | 0.63 | ALDH1A1 (0.36) | NPFFR1NPFFR2ALDH1A1LMNAHTT | |
| SCHEMBL18704077 | 0.63 | RECQL (0.50) | NPFFR1NPFFR2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14842706 | 0.62 | ATP4A (0.44) | NPFFR1NPFFR2ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | NPFFR1 4758/4885NPFFR2 4721/4885ALDH1A1 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.